ArticleNature reviews. Gastroenterology & hepatology2021
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.
Article in Nature reviews. Gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 4 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review.Rheumatology (Oxford, England) · 2026Pooled it
- Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis.Annals of medicine · 2025Pooled it
- Risk of stroke in patients with inflammatory bowel disease: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Anti-tumor Necrosis Factor Alpha Versus Corticosteroids: A 3-fold Difference in the Occurrence of Venous Thromboembolism in Inflammatory Bowel Disease－A Systematic Review and Meta-analysis.Journal of Crohn's & colitis · 2024Pooled it
- Article
- The JAK attack: transforming the management of ulcerative colitis in India.Intestinal research · 2026Review
- A survey on the practices and patterns in the management of acute severe ulcerative colitis in India.Intestinal research · 2026Article
- Administratively Defined Functional Vulnerability and Adverse Short-Term Outcomes in Older Adults Hospitalized with Crohn's Disease Flares: A Propensity-Matched Multicenter Cohort Study.Diseases (Basel, Switzerland) · 2026Article
- Utility of rotational thrombo-elastometry as an objective measure of hypercoagulability in ulcerative colitis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Raising the bar: Utilizing quality improvement tools to increase compliance with clinical care guidelines in inflammatory bowel disease patients.JPGN reports · 2026Article
- From Inflammation to Thrombosis: The Prothrombotic State and Cardiovascular Risk in Inflammatory Bowel Disease.Medicina (Kaunas, Lithuania) · 2026Review
- Association of inflammatory bowel disease with cardiovascular disease, and the mediating role of inflammation: a matched-cohort study.Therapeutic advances in gastroenterology · 2026Article
- Venous Thromboembolism After Total Colectomy in Inflammatory Bowel Disease: Risk Factors and Mortality - a Danish Population-Based Cohort Study.Clinical epidemiology · 2026Article
- Virus-derived serpin reduces immuno-coagulopathic damage in murine colitis by targeting the urokinase-type plasminogen activator receptor (uPAR) and complement.Scientific reports · 2025Article
- Association of histologic and clinical activity with major adverse cardiovascular events in patients with inflammatory bowel disease: A cohort study.Journal of internal medicine · 2025Article
- Impact of venous thromboembolism on mortality in hospitalized patients with inflammatory bowel disease: analysis of the MIMIC-IV database, 2008 to 2022.BMC gastroenterology · 2025Article
- Understanding Inflammatory Bowel Disease in Women From Puberty to Menopause.Gastroenterology & hepatology · 2025Article
- Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease.The Korean journal of internal medicine · 2025Review
- Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study.Paediatric drugs · 2025Article
- Sagittal Sinus Thrombosis and Ischemic Cerebrovascular Accident in a Patient With Ulcerative Colitis: A Case Report.Clinical case reports · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 16 institutions in 12 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 14 international IBD experts and 3 thrombosis experts from 12 countries. Proposed statements were voted upon in an anonymous manner. Agreement was defined as at least 75% of participants voting as 'fully agree' or 'mostly agree' with each statement. For each statement, the level of evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Consensus was reached for 19 statements. Patients with IBD harbour an increased risk of venous and arterial thrombotic events. Thromboprophylaxis is indicated during hospitalization of any cause in patients with IBD. Disease activity is a modifiable risk factor in patients with IBD, and physicians should aim to achieve deep remission to reduce the risk. Exposure to steroids should be limited. Antitumour necrosis factor agents might be associated with a reduced risk of thrombotic events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.